<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0176822</article-id>
<article-id pub-id-type="publisher-id">PONE-D-17-06665</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Specimen preparation and treatment</subject><subj-group><subject>Staining</subject><subj-group><subject>Membrane staining</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Prognosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Specimen preparation and treatment</subject><subj-group><subject>Staining</subject><subj-group><subject>Cell staining</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Specimen preparation and treatment</subject><subj-group><subject>Staining</subject><subj-group><subject>Cytoplasmic staining</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular structures and organelles</subject><subj-group><subject>Cell membranes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer treatment</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis</article-title>
<alt-title alt-title-type="running-head">PD-L1 expression in tumor infiltrating immune cells</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhao</surname>
<given-names>Tiancheng</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Li</surname>
<given-names>Changfeng</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wu</surname>
<given-names>Yanhua</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2612-4285</contrib-id>
<name name-style="western">
<surname>Li</surname>
<given-names>Bingjin</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Zhang</surname>
<given-names>Bin</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Endoscopy Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Division of Clinical Research, First Hospital of Jilin University, Changchun, Jilin, China</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Jilin Provincial Key Laboratory on Molecular and Chemical Genetics, The Second Hospital of Jilin University, Changchun, Jilin, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Yuan</surname>
<given-names>Tifei</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Nanjing Normal University, CHINA</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con">
<p><list list-type="simple"> <list-item>
<p><bold>Conceptualization:</bold> BJL BZ.</p></list-item> <list-item>
<p><bold>Data curation:</bold> TCZ CFL YHW.</p></list-item> <list-item>
<p><bold>Formal analysis:</bold> BZ.</p></list-item> <list-item>
<p><bold>Funding acquisition:</bold> BZ.</p></list-item> <list-item>
<p><bold>Investigation:</bold> TCZ.</p></list-item> <list-item>
<p><bold>Methodology:</bold> TCZ CFL.</p></list-item> <list-item>
<p><bold>Project administration:</bold> BZ.</p></list-item> <list-item>
<p><bold>Resources:</bold> TCZ YHW.</p></list-item> <list-item>
<p><bold>Software:</bold> TCZ.</p></list-item> <list-item>
<p><bold>Supervision:</bold> BJL BZ.</p></list-item> <list-item>
<p><bold>Validation:</bold> BJL BZ.</p></list-item> <list-item>
<p><bold>Visualization:</bold> TCZ YHW.</p></list-item> <list-item>
<p><bold>Writing – original draft:</bold> TCZ BJL BZ.</p></list-item> <list-item>
<p><bold>Writing – review &amp; editing:</bold> TCZ BZ.</p></list-item></list>
</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">zhangbin_bio@163.com</email> (BZ); <email xlink:type="simple">libingjin@jlu.edu.cn</email> (BJL)</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>12</volume>
<issue>4</issue>
<elocation-id>e0176822</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>2</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>4</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-year>2017</copyright-year>
<copyright-holder>Zhao et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0176822"/>
<abstract>
<p>Programmed death-ligand 1 (PD-L1) is a promising target of cancer immune therapy. It not only expressed in tumor cells (TCs) but also up regulated in tumor infiltrating immune cells (TIICs). Although the previous meta-analysis have shown that PD-L1 expression in TCs was a valuable biomarker in predicting cancer prognosis, but few researches systematic evaluated the association between its expression in TIICs and survival of cancer patients. Thus, we performed this meta-analysis to evaluate the prognostic value of PD-L1 expression in TIICs in different types of cancers. Our results are valuable supplements when using PD-L1 expression to predict the survival of cancer patients and to select the beneficial patients from PD-L1 target therapy. PubMed, Embase, Web of Science and the Cochrane Central Search Library were used to perform our systematic literature search. Overall survival (OS) at 5th years and hazard ratios (HRs) were calculated using random effects models. Eighteen studies involving 3674 patients were included. The median positive rate of PD-L1 staining in TIICs was 36.37%. PD-L1 positive expression in TIICs related to a lower risk of death (HR = 0.784, 95%CI: 0.616–0.997, <italic>P</italic> = 0.047). Subgroup analyses found that PD-L1 positive expression in TIICs indicated a better prognosis especially in breast cancer patients (HR = 0.359, <italic>P</italic> = 0.041). When using whole tissue section slides, or using ‘any expression in TIICs’ as a cutoff value to assessing the results of IHC staining, PD-L1 expression in TIICs had a good prognostic value in cancer prognosis (HR = 0.587, <italic>P</italic> = 0.001 and HR = 0.549, <italic>P</italic> = 0.002). Our findings suggested that PD-L1 expression in TIICs was related to a better survival of cancer. The comprehensive evaluation of tumor cells and tumor infiltrating immune cells are required when evaluating the effect of PD-L1 expression on prognosis of cancer in future research.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>the Finance Department of Jilin Province</institution>
</funding-source>
<award-id>sczsy201606</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Zhang</surname>
<given-names>Bin</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This work was supported by the Finance Department of Jilin Province (No.sczsy201606) [<ext-link ext-link-type="uri" xlink:href="http://czt.jl.gov.cn/jlcz/16/tindex.shtml" xlink:type="simple">http://czt.jl.gov.cn/jlcz/16/tindex.shtml</ext-link>].</funding-statement>
</funding-group>
<counts>
<fig-count count="8"/>
<table-count count="2"/>
<page-count count="17"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Cancer remains the most prominent global health-related threat[<xref ref-type="bibr" rid="pone.0176822.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0176822.ref002">2</xref>]. Traditional therapies such as tumorectomy, radiotherapy and chemotherapy are still the main treatments, but their efficacies are unsatisfactory in most cancers, especially in advanced cancers[<xref ref-type="bibr" rid="pone.0176822.ref003">3</xref>]. Recently, variable new cancer treatments have emerged, with immune checkpoint inhibition being one of the most promising therapies[<xref ref-type="bibr" rid="pone.0176822.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0176822.ref005">5</xref>].</p>
<p>Among the immune checkpoint molecules, programmed death 1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1), constitute a pair of negative co-stimulatory molecules that can suppress the functions of T cells and mediate the immune escape of cancers[<xref ref-type="bibr" rid="pone.0176822.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0176822.ref007">7</xref>]. PD-1 and PD-L1 inhibitors were developed by numerous pharmaceuticals companies and well studied in several clinical trials[<xref ref-type="bibr" rid="pone.0176822.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0176822.ref009">9</xref>]. A meta-analysis including 20 trials reported that patients with positive PD-L1 expression might have a decreased risk of mortality compared to negative cases when treated with anti PD-1/PD-L1 antibodies[<xref ref-type="bibr" rid="pone.0176822.ref010">10</xref>]. And the expression of PD-L1 not only linked to the response of immune checkpoint therapy but also associated with the prognosis of several types of cancer, such as non-small-cell lung cancer[<xref ref-type="bibr" rid="pone.0176822.ref011">11</xref>], gastric cancer[<xref ref-type="bibr" rid="pone.0176822.ref012">12</xref>], and breast cancer[<xref ref-type="bibr" rid="pone.0176822.ref013">13</xref>].</p>
<p>Although there has been already a lot of literatures published investigated the associations between PD-L1 expression and cancer prognosis using the method of meta-analysis[<xref ref-type="bibr" rid="pone.0176822.ref014">14</xref>]. However, all of them focused only on the PD-L1 expression in tumor cells. As we know, PD-1/PD-L1 pathway plays an important role in the cancer-specific immune response. PD-L1 is not only expressed in tumor cells but also up-regulated in tumor infiltrating immune cells (TIICs), including tumor infiltrating lymphocytes, mononuclear cells and other immune cells[<xref ref-type="bibr" rid="pone.0176822.ref015">15</xref>–<xref ref-type="bibr" rid="pone.0176822.ref017">17</xref>]. Current clinical trials have shown that the expression of PD-L1 in TIICs is also indicative of a higher response rate to PD-L1/PD-1 targeted therapy[<xref ref-type="bibr" rid="pone.0176822.ref018">18</xref>, <xref ref-type="bibr" rid="pone.0176822.ref019">19</xref>]. Therefore, not only tumor cell-based but also immune cell-based PD-L1 expression appears to be clinically valuable. Recently, a number of studies have reported that the expression of PD-L1 in TIICs which was correlated with the survival of patients with tumors, but have failed to reach consistent conclusions [<xref ref-type="bibr" rid="pone.0176822.ref020">20</xref>–<xref ref-type="bibr" rid="pone.0176822.ref026">26</xref>]. In addition, there has been no research systematic evaluates the predicted value of PD-L1 positive expression in TIICs in cancer prognosis.</p>
<p>Thus, we performed this meta-analysis to evaluate the prognostic value of PD-L1 expression in TIICs in different types of cancers. Our results are valuable supplements when using PD-L1 expression to predict the survival of cancer patients and to select the beneficial patients from PD-L1 target therapy.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec003">
<title>Search strategy</title>
<p>PubMed, Embase, Web of Science and the Cochrane Central Search Library were used to perform our systematic literature search (until December 2016). Key words used included “programmed death-ligand 1 or PD-L1 or B7-H1 or CD274” and “tumor infiltrating lymphocyte or TIL or tumor infiltrating immune cells or TIIC or tumor infiltrating mononuclear cells or TIMC or tumor stroma” and “cancer or carcinoma or tumor” and “prognosis or survival”; the results were limited to human studies. In addition, we searched the reference lists of the reviews on related topics by hand to identify additional studies.</p>
</sec>
<sec id="sec004">
<title>Inclusion and exclusion criteria</title>
<p>The eligible studies were included in this meta-analysis based on the following criteria: (1) PD-L1 expression has been measured by immunohistochemistry (IHC) stain in tumor infiltrating immune cells rather than in tumor cells; (2) studies reported 5-year OS, HR with 95% confidence interval (95% CIs), or reported original survival curves; (3) studies were published in English, and their full texts were available. Exclusion criteria for this study were as follows: (1) conference abstracts, letters, reviews and unpublished studies; and (2) insufficient data to report the hazard ratios and 95% CI, or could not extract the data from Kaplan-Meier curves. If duplicate data presented in more than one study, the largest or most recent study was included.</p>
</sec>
<sec id="sec005">
<title>Data extraction and quality assessment</title>
<p>Two reviewers (Zhao TC and Wu YH) identified relevant articles independently. The details of these surveys included the author’s name, date of publication, type of cancer, type of pathological section, number of patients, tumor stage, age of patients, duration of follow up, antibody, staining location, and cut-off value in assessing the positive expression of PD-L1 in tumor infiltrating immune cells. Newcastle-Ottawa Scale (NOS) was used for quality assessment[<xref ref-type="bibr" rid="pone.0176822.ref027">27</xref>]. NOS scores no less than 6 were defined as high-quality studies.</p>
</sec>
<sec id="sec006">
<title>Statistical analysis</title>
<p>Data were analyzed using STATA version 12.0 (STATA Corporation, College Station, TX, USA). The 3-year OS, 5-year OS, HR and 95%CI were extracted from the original studies, tables or recalculated from Kaplan—Meier curves using the program of Engauge Digitizer (<ext-link ext-link-type="uri" xlink:href="http://sourceforge.net/projects/digitizer/" xlink:type="simple">http://sourceforge.net/projects/digitizer/</ext-link>), and applied using the Mantel—Haenszel random effect model. I<sup>2</sup>[<xref ref-type="bibr" rid="pone.0176822.ref028">28</xref>] was used to determine the heterogeneity of the selected studies. Subgroup analysis and sensitivity analysis were carrying out to assess the potential contributions of different type of tumors and different cutoff values for defining PD-L1 expression in TIICs. Egger’s regression asymmetry test[<xref ref-type="bibr" rid="pone.0176822.ref029">29</xref>] and Begg’s adjusted rank correlation[<xref ref-type="bibr" rid="pone.0176822.ref030">30</xref>] were performed to evaluate the potential publication bias. All tests were two-sided, and <italic>P</italic>&lt;0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="sec007" sec-type="results">
<title>Results</title>
<sec id="sec008">
<title>Identification of eligible studies</title>
<p>The search results shown in <xref ref-type="fig" rid="pone.0176822.g001">Fig 1</xref> identified 603 studies from the initial database. After careful manual selection and review of these articles, 18 studies with full text and available data according to the inclusion and exclusion criteria were included in the final analysis (<xref ref-type="fig" rid="pone.0176822.g001">Fig 1</xref>). And the PRISMA checklist was showed in <xref ref-type="supplementary-material" rid="pone.0176822.s004">S1 File</xref>.</p>
<fig id="pone.0176822.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0176822.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flow diagram of the literature search and study selection for the meta-analysis.</title>
<p>The flow diagram shows eligible publications at each stage of the analysis process. The database search was conducted in December 2016.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec009">
<title>Description of studies</title>
<p>The characteristics of the 18 studies summarized in <xref ref-type="table" rid="pone.0176822.t001">Table 1</xref>. All of the studies assessed PD-L1 expression in tumor infiltrating immune cells using immunohistochemistry techniques. Seven studies evaluated cancers of the digestive system (5 gastric cancers, 1 esophageal squamous cell carcinoma and 1 colorectal cancer), two evaluated cancers of the urinary system (1 urothelial carcinoma and 1 renal cell carcinoma), two evaluated breast cancer, two evaluated lung cancer, and one each evaluated ovarian high grade serous carcinoma, extranodal NK/T-cell lymphoma, head and neck cancer, diffuse large B-cell lymphoma and spinal chordoma. In total, 3674 subjects were included in our meta-analysis.</p>
<table-wrap id="pone.0176822.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0176822.t001</object-id>
<label>Table 1</label> <caption><title>Characteristics of the studies included.</title></caption>
<alternatives>
<graphic id="pone.0176822.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">No</th>
<th align="center">Study, Year</th>
<th align="center">Cancer types</th>
<th align="center">Tissue slides</th>
<th align="center">No. of patients</th>
<th align="center">Age (range)</th>
<th align="center">Tumor stages<xref ref-type="table-fn" rid="t001fn002"><sup>a</sup></xref></th>
<th align="center">Follow up (months)</th>
<th align="center">PD-L1 NO (+/-)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">1</td>
<td align="left">Bellmunt J,2015[<xref ref-type="bibr" rid="pone.0176822.ref020">20</xref>]</td>
<td align="left">urothelial carcinoma</td>
<td align="center">TMAs</td>
<td align="center">89</td>
<td align="center">NR</td>
<td align="center">IV (metastatic)</td>
<td align="center">1–24</td>
<td align="center">33/56</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">Boger C,2016[<xref ref-type="bibr" rid="pone.0176822.ref021">21</xref>]</td>
<td align="left">gastric cancer</td>
<td align="center">Whole</td>
<td align="center">465</td>
<td align="center">68 (median)</td>
<td align="center">I-IV</td>
<td align="center">0.2–109</td>
<td align="center">160/291</td>
</tr>
<tr>
<td align="left">3</td>
<td align="left">Choueiri TK,2014[<xref ref-type="bibr" rid="pone.0176822.ref022">22</xref>]</td>
<td align="left">nonclear-cell renal cell carcinoma</td>
<td align="center">NR</td>
<td align="center">101</td>
<td align="center">24–81</td>
<td align="center">I-IV</td>
<td align="center">60(median)</td>
<td align="center">57/44</td>
</tr>
<tr>
<td align="left">4</td>
<td align="left">Darb-Esfahani S,2015[<xref ref-type="bibr" rid="pone.0176822.ref023">23</xref>]</td>
<td align="left">ovarian high grade serous carcinoma</td>
<td align="center">TMAs</td>
<td align="center">200</td>
<td align="center">60 (median)</td>
<td align="center">I-IV (FIGO)</td>
<td align="center">37.9(median)</td>
<td align="center">60/140</td>
</tr>
<tr>
<td align="left">5</td>
<td align="left">Hatogai K,2016[<xref ref-type="bibr" rid="pone.0176822.ref024">24</xref>]</td>
<td align="left">esophageal squamous cell carcinoma</td>
<td align="center">TMAs</td>
<td align="center">196</td>
<td align="center">42–87</td>
<td align="center">I-IV</td>
<td align="center">1.2–127.2</td>
<td align="center">119/77</td>
</tr>
<tr>
<td align="left">6</td>
<td align="left">Hou J,2014[<xref ref-type="bibr" rid="pone.0176822.ref025">25</xref>]</td>
<td align="left">gastric cancer</td>
<td align="center">NR</td>
<td align="center">111</td>
<td align="center">18–96</td>
<td align="center">I-IV</td>
<td align="center">NR</td>
<td align="center">71/40</td>
</tr>
<tr>
<td align="left">7</td>
<td align="left">Jo J-C,2016[<xref ref-type="bibr" rid="pone.0176822.ref026">26</xref>]</td>
<td align="left">extranodal NK/T-cell lymphoma</td>
<td align="center">NR</td>
<td align="center">79</td>
<td align="center">19–79</td>
<td align="center">I-IV</td>
<td align="center">52.4(median)</td>
<td align="center">62/17</td>
</tr>
<tr>
<td align="left">8</td>
<td align="left">Kawazoe A,2016[<xref ref-type="bibr" rid="pone.0176822.ref031">31</xref>]</td>
<td align="left">gastric cancer</td>
<td align="center">TMAs</td>
<td align="center">383</td>
<td align="center">26–92</td>
<td align="center">III-IV</td>
<td align="center">NR</td>
<td align="center">241/142</td>
</tr>
<tr>
<td align="left">9</td>
<td align="left">Kim HR,2016[<xref ref-type="bibr" rid="pone.0176822.ref032">32</xref>]</td>
<td align="left">head and neck cancer</td>
<td align="center">TMAs</td>
<td align="center">402</td>
<td align="center">22–88</td>
<td align="center">I-IV</td>
<td align="center">46.3 (median)</td>
<td align="center">112/290</td>
</tr>
<tr>
<td align="left">10</td>
<td align="left">Kiyasu J,2015[<xref ref-type="bibr" rid="pone.0176822.ref033">33</xref>]</td>
<td align="left">diffuse large B-cell lymphoma</td>
<td align="center">NR</td>
<td align="center">239</td>
<td align="center">30–92</td>
<td align="center">I-IV</td>
<td align="center">NR</td>
<td align="center">53/186</td>
</tr>
<tr>
<td align="left">11</td>
<td align="left">Li X,2016[<xref ref-type="bibr" rid="pone.0176822.ref034">34</xref>]</td>
<td align="left">triple-negative breast cancer</td>
<td align="center">Whole</td>
<td align="center">136</td>
<td align="center">NR</td>
<td align="center">NR</td>
<td align="center">NR</td>
<td align="center">32/104</td>
</tr>
<tr>
<td align="left">12</td>
<td align="left">Paulsen E-E,2016[<xref ref-type="bibr" rid="pone.0176822.ref035">35</xref>]</td>
<td align="left">none small cell lung cancer</td>
<td align="center">TMAs</td>
<td align="center">505</td>
<td align="center">28–85</td>
<td align="center">I-IIIA</td>
<td align="center">86(34–267)</td>
<td align="center">182/323</td>
</tr>
<tr>
<td align="left">13</td>
<td align="left">Saito R,2016[<xref ref-type="bibr" rid="pone.0176822.ref036">36</xref>]</td>
<td align="left">EBV positive gastric cancer</td>
<td align="center">TMAs</td>
<td align="center">96</td>
<td align="center">40–90</td>
<td align="center">I-IV</td>
<td align="center">3-262(range)</td>
<td align="center">43/53</td>
</tr>
<tr>
<td align="left">14</td>
<td align="left">Sun W-Y,2016[<xref ref-type="bibr" rid="pone.0176822.ref037">37</xref>]</td>
<td align="left">triple negative breast cancer</td>
<td align="center">TMAs</td>
<td align="center">218</td>
<td align="center">NR</td>
<td align="center">I-IIIB</td>
<td align="center">0.2–98 (range)</td>
<td align="center">80/138</td>
</tr>
<tr>
<td align="left">15</td>
<td align="left">Thompson ED, 2016[<xref ref-type="bibr" rid="pone.0176822.ref038">38</xref>]</td>
<td align="left">gastric adenocarcinomas</td>
<td align="center">Whole</td>
<td align="center">33</td>
<td align="center">21–92</td>
<td align="center">I-IV</td>
<td align="center">40(median)</td>
<td align="center">15/18</td>
</tr>
<tr>
<td align="left">16</td>
<td align="left">Wang L,2016[<xref ref-type="bibr" rid="pone.0176822.ref039">39</xref>]</td>
<td align="left">Colorectal cancer</td>
<td align="center">TMAs</td>
<td align="center">262</td>
<td align="center">28–75</td>
<td align="center">II-III</td>
<td align="center">43.5(mean) (21–68)</td>
<td align="center">55/207</td>
</tr>
<tr>
<td align="left">17</td>
<td align="left">Yang C-Y,2016[<xref ref-type="bibr" rid="pone.0176822.ref040">40</xref>]</td>
<td align="left">pulmonary squamous cell carcinoma</td>
<td align="center">Whole</td>
<td align="center">105</td>
<td align="center">40–84</td>
<td align="center">IA-IB</td>
<td align="center">79(mean)</td>
<td align="center">31/74</td>
</tr>
<tr>
<td align="left">18</td>
<td align="left">Zou MX,2016[<xref ref-type="bibr" rid="pone.0176822.ref041">41</xref>]</td>
<td align="left">spinal chordoma</td>
<td align="center">Whole</td>
<td align="center">54</td>
<td align="center">23–79</td>
<td align="center">I-III</td>
<td align="center">42.39(mean) (5–158)</td>
<td align="center">12/42</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>NR, not reported; TMAs, tissue microarrays; EBV, Epstein-Barr virus; FIGO: International Federation of Gynecology and Obstetrics</p></fn>
<fn id="t001fn002"><p><sup>a</sup> Unless otherwise noted, Tumor stage was classified according to the AJCC/UICC staging system</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec010">
<title>Evaluation of PD-L1 expression in TIICs</title>
<p>The antibodies, cutoff values and staining locations used in the evaluation of PD-L1 expression in TIICs of the included studies are shown in <xref ref-type="table" rid="pone.0176822.t002">Table 2</xref>. Clone E1L3N was used in four studies, and Clone SP142 was used in three studies. The cutoff values in assessing the positive expression of PD-L1 in TIICs were divided into 4 types: (1) proportion of stained cells greater than 5%, (2) proportion of stained cells greater than 1%, (3) any expression of PD-L1 in TIICs and (4) others. Most studies considered that the positive staining was located in the cell membrane (12 of 18 studies); whereas others thought both membranous and cytoplasmic staining could be considered as positive expression. The median positive rate of PD-L1 expression in TIICs was 36.37%.</p>
<table-wrap id="pone.0176822.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0176822.t002</object-id>
<label>Table 2</label> <caption><title>Detection of the PD-L1 expression in TIICs in the selected studies.</title></caption>
<alternatives>
<graphic id="pone.0176822.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">No</th>
<th align="center">Study, Year</th>
<th align="center">Antibody</th>
<th align="center">Cutoff value of PD-L1 positive expression in TIICs</th>
<th align="center">Staining location</th>
<th align="center">3-year OS(+/-)%</th>
<th align="center">5-year OS (+/-)%</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">1</td>
<td align="left">Bellmunt J,2015 [<xref ref-type="bibr" rid="pone.0176822.ref020">20</xref>]</td>
<td align="center">405.9A11</td>
<td align="left">Absent (0), focal (1), mild (2), moderate (3), and severe (4); 2–4 were considered positive</td>
<td align="left">Membrane</td>
<td align="center">NR</td>
<td align="center">NR</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">Boger C,2016 [<xref ref-type="bibr" rid="pone.0176822.ref021">21</xref>]</td>
<td align="center">E1L3N</td>
<td align="left">The percentage of positive cells: 0 (negative), 1 (1–5% positive), 2 (6–20%) and 3 (&gt;20%); Score &gt;1 were considered positive</td>
<td align="left">Membrane</td>
<td align="center">39.4/18.8</td>
<td align="center">23.8/12.0</td>
</tr>
<tr>
<td align="left">3</td>
<td align="left">Choueiri TK,2014 [<xref ref-type="bibr" rid="pone.0176822.ref022">22</xref>]</td>
<td align="center">405.9A11</td>
<td align="left">According to the percentages of PD-L1 positive TIMC (0% = 0, &lt;5% = 1, ≥5% = 2); Score &gt;0 were considered positive</td>
<td align="left">Membrane</td>
<td align="center">84.5/94.9</td>
<td align="center">73.7/84.1</td>
</tr>
<tr>
<td align="left">4</td>
<td align="left">Darb-Esfahani S [<xref ref-type="bibr" rid="pone.0176822.ref023">23</xref>]</td>
<td align="center">EPR1161</td>
<td align="left">&gt;20/mm<sup>2</sup> were considered positive</td>
<td align="left">Membrane/ Cytoplasm</td>
<td align="center">NR</td>
<td align="center">NR</td>
</tr>
<tr>
<td align="left">5</td>
<td align="left">Hatogai K,2016 [<xref ref-type="bibr" rid="pone.0176822.ref024">24</xref>]</td>
<td align="center">NR</td>
<td align="left">Any expression of PD-L1 in TIICs in the core were considered positive</td>
<td align="left">Membrane</td>
<td align="center">58.0/40.9</td>
<td align="center">52.9/33.8</td>
</tr>
<tr>
<td align="left">6</td>
<td align="left">Hou J,2014 [<xref ref-type="bibr" rid="pone.0176822.ref025">25</xref>]</td>
<td align="center">NR (Abcam)</td>
<td align="left">Proportion of stained cells &gt;5% were considered positive</td>
<td align="left">Membrane/ cytoplasm</td>
<td align="center">42.3/70.0</td>
<td align="center">NR</td>
</tr>
<tr>
<td align="left">7</td>
<td align="left">Jo J-C,2016 [<xref ref-type="bibr" rid="pone.0176822.ref026">26</xref>]</td>
<td align="center">NR (R&amp;D Systems)</td>
<td align="left">More than 5% cells was stained were considered positive</td>
<td align="left">Membrane/ cytoplasm</td>
<td align="center">54.3/30.1</td>
<td align="center">48.6/30.1</td>
</tr>
<tr>
<td align="left">8</td>
<td align="left">Kawazoe A,2016 [<xref ref-type="bibr" rid="pone.0176822.ref031">31</xref>]</td>
<td align="center">SP142</td>
<td align="left">&lt;1% (0), 1% to 9% (2), 10% to 19% (3), ≥20% (4); ≥1% were considered positive</td>
<td align="left">Membrane</td>
<td align="center">62.9/59.1</td>
<td align="center">55.5/48.5</td>
</tr>
<tr>
<td align="left">9</td>
<td align="left">Kim HR,2016 [<xref ref-type="bibr" rid="pone.0176822.ref032">32</xref>]</td>
<td align="center">SP142</td>
<td align="left">Proportion of stained cells &gt;5% were considered positive</td>
<td align="left">Membrane/ cytoplasm</td>
<td align="center">93.7/80.1</td>
<td align="center">90.2/75.5</td>
</tr>
<tr>
<td align="left">10</td>
<td align="left">Kiyasu J,2015 [<xref ref-type="bibr" rid="pone.0176822.ref033">33</xref>]</td>
<td align="center">ab174838</td>
<td align="left">PD-L1 nonmalignant stromal cells represented 20% or more of the total tissue were considered positive</td>
<td align="left">Membrane/ cytoplasm</td>
<td align="center">63.3/72.9</td>
<td align="center">51.6/61.1</td>
</tr>
<tr>
<td align="left">11</td>
<td align="left">Li X,2016 [<xref ref-type="bibr" rid="pone.0176822.ref034">34</xref>]</td>
<td align="center">E1L3N</td>
<td align="left">Any stromal PD-L1 expression were considered positive</td>
<td align="left">Membrane</td>
<td align="center">NR</td>
<td align="center">NR</td>
</tr>
<tr>
<td align="left">12</td>
<td align="left">Paulsen E-E,2016 [<xref ref-type="bibr" rid="pone.0176822.ref035">35</xref>]</td>
<td align="center">E1L3N</td>
<td align="left">Absent (0), 1% to 49% (1), 50% to 75% (2), or &gt; 75% (3) &gt;1.5 were considered positive</td>
<td align="left">Membrane/ cytoplasm</td>
<td align="center">NR</td>
<td align="center">52/44</td>
</tr>
<tr>
<td align="left">13</td>
<td align="left">Saito R,2016 [<xref ref-type="bibr" rid="pone.0176822.ref036">36</xref>]</td>
<td align="center">E1L3N</td>
<td align="left">Simply classified into negative or positive groups depending on the proportion of stained cells (cutoff value: 1%)</td>
<td align="left">Membrane</td>
<td align="center">88.0/91.7</td>
<td align="center">80.9/91.7</td>
</tr>
<tr>
<td align="left">14</td>
<td align="left">Sun W-Y,2016 [<xref ref-type="bibr" rid="pone.0176822.ref037">37</xref>]</td>
<td align="center">28–8</td>
<td align="left">any immunostaining were considered positive</td>
<td align="left">Membrane</td>
<td align="center">NR</td>
<td align="center">NR</td>
</tr>
<tr>
<td align="left">15</td>
<td align="left">Thompson ED, 2016 [<xref ref-type="bibr" rid="pone.0176822.ref038">38</xref>]</td>
<td align="center">5H1</td>
<td align="left">&gt;1% of PD-L1 staining on TIL or TAM was considered positive."</td>
<td align="left">Membrane</td>
<td align="center">71.2/76.0</td>
<td align="center">51.6/61.1</td>
</tr>
<tr>
<td align="left">16</td>
<td align="left">Wang L,2016[<xref ref-type="bibr" rid="pone.0176822.ref039">39</xref>]</td>
<td align="center">SP142</td>
<td align="left">&lt;1% (0), 1% to 4% (1), 5% to 9% (2), ≥10% (3); scores of 2 and 3 were considered positive</td>
<td align="left">Membrane</td>
<td align="center">66.5/80.1</td>
<td align="center">57.4/72.5</td>
</tr>
<tr>
<td align="left">17</td>
<td align="left">Yang C-Y,2016 [<xref ref-type="bibr" rid="pone.0176822.ref040">40</xref>]</td>
<td align="center">17952–1 -AP</td>
<td align="left">Proportion of stained cells &gt;5% were considered positive</td>
<td align="left">Membrane</td>
<td align="center">NR</td>
<td align="center">NR</td>
</tr>
<tr>
<td align="left">18</td>
<td align="left">Zou MX,2016 [<xref ref-type="bibr" rid="pone.0176822.ref041">41</xref>]</td>
<td align="center">ab174838</td>
<td align="left">Absent (0), rare/few (1), moderate (2), prominent (3), ≥2 were considered positive</td>
<td align="left">Membrane</td>
<td align="center">87.6/93.3</td>
<td align="center">72.7/32.5</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>NR, not reported; TIICs, tumor infiltrating immune cells; TIL, tumor-infiltrating lymphocyte; TAM, tumor-associated macrophages</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec011">
<title>PD-L1 expression in TIICs and five-year OS</title>
<p>Twelve studies reported data for 5-year OS. As shown in <xref ref-type="fig" rid="pone.0176822.g002">Fig 2</xref>, PD-L1 positive expression in TIICs seems to be associated with a better 5-year OS of cancer patients, though it did not reach statistical difference (OR = 0.778, 95%CI: 0.534–1.134, <italic>P</italic> = 0.192). Because of the significant heterogeneity among studies (I<sup>2</sup> = 72%), subgroup analyses were conducted to assess whether the heterogeneity was due to different cancer types and cutoff values. Six studies provided the 5-year OS for digestive system cancers; others reported different types of cancer (<xref ref-type="supplementary-material" rid="pone.0176822.s001">S1 Fig</xref>). In the stratified analysis by cancer types, PD-L1 positive expression in TIICs of digestive system cancers was not associated with 5-year OS (OR = 0.862, 95%CI: 0.438–1.697, <italic>P</italic> = 0.667). Further, I<sup>2</sup> was calculated to be 76.5%, which indicated that the heterogeneity was not due to different cancer types. We then conducted a subgroup analysis according to different cutoff values. When the cutoff value was defined as ‘proportion of stained cells greater than 5%’, PD-L1 expression in TIICs seems to be associated with a better cancer survival (OR = 0.662, 95% CI: 0.429–1.022, <italic>P</italic> = 0.062, I<sup>2</sup> = 72.9%). When using the cutoff value of ‘proportion of stained cells greater than 1%’ to distinguish the positive and negative expression of PD-L1 in TIICs, the opposite trend has been reported (OR = 1.958, 95%CI: 0.987–1.134, <italic>P</italic> = 0.055, I<sup>2</sup> = 0%; <xref ref-type="fig" rid="pone.0176822.g003">Fig 3</xref>).</p>
<fig id="pone.0176822.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0176822.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Forest plot shows the associations between PD-L1 expression in TIICs and five year overall survival of cancer patients.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.g002" xlink:type="simple"/>
</fig>
<fig id="pone.0176822.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0176822.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Subgroup analysis by different cutoff values shows the associations between PD-L1 expression in TIICs and five year overall survival of cancer patients.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.g003" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec012">
<title>PD-L1 expression in TIICs and time-to-event index</title>
<p>A total of 18 eligible studies were pooled to analyze the predictive value of TIICs expressed PD-L1 in cancer prognosis using HR and 95%CIs. <xref ref-type="fig" rid="pone.0176822.g004">Fig 4</xref> shown that PD-L1 expression in TIICs indicated a decreased risk of death (HR = 0.784, 95%CI: 0.616–0.997, <italic>P</italic> = 0.047). Similar to 5-year OS, significant heterogeneity was noted (I<sup>2</sup> = 67.7%, <italic>P</italic>&lt;0.001). Exploratory subgroup analysis suggested that PD-L1 expression in TIICs indicted a lower risk of death in patients with breast cancer (HR = 0.359, 95%CI: 0.134–0.961, <italic>P</italic> = 0.041, I<sup>2</sup> = 0%; <xref ref-type="supplementary-material" rid="pone.0176822.s002">S2 Fig</xref>). As shown in <xref ref-type="fig" rid="pone.0176822.g005">Fig 5</xref>, PD-L1 in TIICs was only associated with improved overall survival in those studies using cutoff value of ‘Any positive staining in immune cells’ (HR = 0.549, 95%CI = 0.378–0.798, <italic>P</italic> = 0.002, I<sup>2</sup> = 0%). We also conducted a subgroup analysis according to different types of pathological sections (the whole tissue section slides or tissue microarrays). PD-L1 in TIICs was correlated to a favorable prognosis in those studies using whole tissue section slides in conducting the immunohistochemical stain (HR = 0.587, 95%CI: 0.425–0.810, <italic>P</italic> = 0.001, I<sup>2</sup> = 11.9%, <xref ref-type="fig" rid="pone.0176822.g006">Fig 6</xref>). Additionally, genetic differences will contribute to the heterogeneity between individual studies. The ethnicities of included studies were divided into two parts; Asian and non-Asian. Positive expression of PD-L1 in TIICs was an indicator of a favorable prognosis, only in non-Asian cancer patients (HR = 0.709, 95%CI: 0.511–0.985, <italic>P</italic> = 0.040, I<sup>2</sup> = 63.9%, <xref ref-type="fig" rid="pone.0176822.g007">Fig 7</xref>).</p>
<fig id="pone.0176822.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0176822.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Forest plot of hazard ratios shows the associations between PD-L1 expression in TIICs and cancer prognosis.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.g004" xlink:type="simple"/>
</fig>
<fig id="pone.0176822.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0176822.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Forest plot of hazard ratios form subgroup analysis by different cutoff values shows the associations between PD-L1 expression in TIICs and cancer prognosis.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.g005" xlink:type="simple"/>
</fig>
<fig id="pone.0176822.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0176822.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Forest plot of hazard ratios form subgroup analysis by different types of pathological sections shows the associations between PD-L1 expression in TIICs and cancer prognosis.</title>
<p>TMAs, tissue microarrays.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.g006" xlink:type="simple"/>
</fig>
<fig id="pone.0176822.g007" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0176822.g007</object-id>
<label>Fig 7</label>
<caption>
<title>Forest plot of hazard ratios form subgroup analysis by different ethnicity shows the associations between PD-L1 expression in TIICs and cancer prognosis.</title>
<p>TMAs, tissue microarrays.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.g007" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec013">
<title>Sensitivity and publication bias analyses</title>
<p>Omitting any individual study did not influence the combined results for 5-year OS or HR (<xref ref-type="supplementary-material" rid="pone.0176822.s003">S3 Fig</xref>). The funnel plot for the relationship between PD-L1 expression in TIICs and cancer prognosis is presenting in <xref ref-type="fig" rid="pone.0176822.g008">Fig 8</xref>. For 5-year OS the P values for Egger’s and Begg’s tests were 0.714 and 0.891. For hazard ratio, the results from Egger’s and Begg’s tests also revealed that there was no publication bias in this meta-analysis (<italic>P</italic> = 0.986 and <italic>P</italic> = 0.733, respectively).</p>
<fig id="pone.0176822.g008" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0176822.g008</object-id>
<label>Fig 8</label>
<caption>
<title>Begg’s funnel plots show the publication bias.</title>
<p>(A) Begg’s funnel plot for 5-years OS (B) Begg’s funnel plot for HR.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.g008" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec014" sec-type="conclusions">
<title>Discussion</title>
<p>Anti-PD-1/PD-L1 therapy has been discussed as a potential effective strategy for cancer treatment, and numerous studies have reported the positive expression of PD-L1 in tumor cells as a predictive biomarker for the response to PD-1/PD-L1 blocking therapy[<xref ref-type="bibr" rid="pone.0176822.ref042">42</xref>]. Simultaneously, the expression of PD-L1 has always been considered a predicted biomarker in cancer prognosis[<xref ref-type="bibr" rid="pone.0176822.ref014">14</xref>]. Not only tumor cells, but also tumor-infiltrating immune cells could express PD-L1. Previous studies have only focused on PD-L1 expression in tumor cells, but recent studies indicated that the PD-L1 expression in TIICs also played an important role in tumor immune escape and influenced tumor progression[<xref ref-type="bibr" rid="pone.0176822.ref016">16</xref>, <xref ref-type="bibr" rid="pone.0176822.ref017">17</xref>, <xref ref-type="bibr" rid="pone.0176822.ref031">31</xref>, <xref ref-type="bibr" rid="pone.0176822.ref036">36</xref>]. These leading studies highlighted that PD-L1 expression in TIICs could also serve as a prognostic biomarker, and further inform the responses to anti-PD-1/PD-L1 treatment. In this meta-analysis of data from 18 studies, with a cohort of 3674 cancer patients, we firstly provided a quantitative estimate to the prognostic value of PD-L1 expression in TIICs in cancer patients.</p>
<p>Five-year overall survival and hazard ratio were both important indexes in cancer prognostic evaluation. Our results shown that, PD-L1 in TIICs was significantly associated with a decreased risk of death (HR = 0.784, 95%CI: 0.616–0.997, <italic>P</italic> = 0.047) compared with patients with PD-L1 negative expression in TIICs. A similar trend has observed when using 5-year OS to evaluate the predictive value of PD-L1 in TIICs in cancer prognosis, but the P value was not statistically significant. Our results were quite different from the published meta-analysis which shown that PD-L1 expression in tumor cells was associated with a worse prognosis of cancer. Different mechanisms between PD-L1 expression in TCs and TIICs might explain the inconsistent results. Transcriptome analyses indicated that, PD-L1 expression in TCs was up regulated through the tumor-intrinsic mechanisms, including the activation of endogenous oncogene and related signaling pathway[<xref ref-type="bibr" rid="pone.0176822.ref043">43</xref>]. However, PD-L1 expression in TIICs could be driven by adaptive mechanisms such like exogenous inflammation mediated immune attack and then reflected pre-existing immunity[<xref ref-type="bibr" rid="pone.0176822.ref044">44</xref>, <xref ref-type="bibr" rid="pone.0176822.ref045">45</xref>]. In other words, comparing with tumor cells, the tumor infiltrating immune cells based PD-L1 expression has stronger relations with cancer immune response, and depends on tumor microenvironments. In fact, PD-L1 positive expression in TIICs was positive correlated to the quantity of multiple tumor-infiltrating immune cells, such as CD4<sup>+</sup> T lymphocytes and CD8<sup>+</sup>T lymphocytes. Since the high expression of CD4<sup>+</sup> T lymphocytes and CD8<sup>+</sup> T lymphocytes was associated with better outcomes of cancer patients[<xref ref-type="bibr" rid="pone.0176822.ref043">43</xref>, <xref ref-type="bibr" rid="pone.0176822.ref046">46</xref>], the PD-L1 expression in TIICs was possibly associated with better cancer prognosis. Although PD-L1 expression could mediate the occurrence of cancer immune escape, it also indicated an effective immune response, especially with a favorable profile of immune microenvironments in the early stage of the cancer immune response[<xref ref-type="bibr" rid="pone.0176822.ref040">40</xref>].</p>
<p>According to the results of subgroup analysis, different types of pathological sections and different definition of cutoff values when conducting and assessing the IHC stain could partly explain the large heterogeneity among individual studies. Half of the studies using tissue microarrays (TMAs) to conduct the IHC stain. TMAs usually contain limited tissue (2.0mm) and extract from the central part of tumors. Compare with the whole tissue section slides, TMAs may have less representativeness, especially in assessing the biomarkers expressed in tumor infiltrating immune cells. The subgroup analysis according to different types of pathological sections showed that when using whole section slides to investigate PD-L1 positive expression in TIICs, the heterogeneity among different studies was the lowest. It indicates that using whole section slides to conduct the IHC staining should be recommended in related clinical trials and treatments. Additionally, the appropriate cutoff value in validating the positive expression of PD-L1 remains contentious. Subgroup analysis with different cutoff values has shown that there was a contradictory trend when using the cutoff value of ‘5%’ or ‘1%’ in evaluating the correlations of PD-L1 positive expression in TIICs with survival of cancer patients. Therefore, a multi-classification of cutoff values for assessing PD-L1 expression in TIICs may be feasible and reasonable. Asian and non-Asian cancer patients exhibit distinct tumor immunity signatures. For instance, in gastric cancer, non-Asian patients show significantly higher expression level of T-cell markers, including CD3 and CD8, and lower expression level of immunosuppressive T-regulatory cell markers, such as FOXP3 compared to Asian gastric patients[<xref ref-type="bibr" rid="pone.0176822.ref047">47</xref>]. Immune-related biomarkers differentially expressed between Asian and non-Asian cancer patients who was related to immune function. These differences may affect the associations between PD-L1 expression and survival of cancer patients.</p>
<p>Several limitations should be acknowledged in our study. First, in several studies, when 5-year OS and HRs not provided in the original studies, we derived the indexes from Kaplan–Meier survival curves; six of the 18 studies did not provide 5-year OS or original Kaplan–Meier survival curves. As a result, only 12 studies were available to calculate the association of PD-L1 expression in TIICs with five-year OS, which could affect the level of evidence. Second, not all of the included studies using the multiple Cox regression to estimate the independent prognostic value of PD-L1 expression in TIICs in cancer. Thus, the results from all of the studies could not be further stratified with the same confounding factors, and further studies with more confounding factor adjustments need to be conducted.</p>
</sec>
<sec id="sec015" sec-type="conclusions">
<title>Conclusions</title>
<p>Despite these limitations, we have demonstrated that PD-L1 expression in TIICs might serve as a new biomarker for prognosticating the survival of cancer patients. Thus, incorporating the expression of tumor-infiltrating immune cells into the classification of PD-L1 expression is necessary. Our results may be useful supplements when using PD-L1 expression to predict the survival of cancer patients and to select the beneficial patients from anti-PD-L1 treatment.</p>
</sec>
<sec id="sec016">
<title>Supporting information</title>
<supplementary-material id="pone.0176822.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.s001" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Subgroup analysis by different types of cancers shows the associations between PD-L1 expression in TIICs and five year overall survival of cancer patients.</title>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0176822.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.s002" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>Forest plot of hazard ratios form subgroup analysis by types of cancers shows the associations between PD-L1 expression in TIICs and cancer prognosis.</title>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0176822.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.s003" xlink:type="simple">
<label>S3 Fig</label>
<caption>
<title>Sensitivity analyses show the associations between PD-L1 expression in TIICs and cancer prognosis.</title>
<p>(A) Sensitivity analysis for 5-years OS (B) Sensitivity analysis for HR.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0176822.s004" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.s004" xlink:type="simple">
<label>S1 File</label>
<caption>
<title>PRISMA 2009 checklist.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0176822.s005" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0176822.s005" xlink:type="simple">
<label>S2 File</label>
<caption>
<title>Full electronic search strategy in PUBMED.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0176822.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Siegel</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Miller</surname> <given-names>KD</given-names></name>, <name name-style="western"><surname>Jemal</surname> <given-names>A</given-names></name>. <article-title>Cancer Statistics, 2017</article-title>. <source>CA: a cancer journal for clinicians</source>. <year>2017</year>;<volume>67</volume>(<issue>1</issue>):<fpage>7</fpage>–<lpage>30</lpage>. Epub 2017/01/06.</mixed-citation></ref>
<ref id="pone.0176822.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Zheng</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Baade</surname> <given-names>PD</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Zeng</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Bray</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Cancer statistics in China, 2015</article-title>. <source>CA Cancer J Clin</source>. <year>2016</year>;<volume>66</volume>(<issue>2</issue>):<fpage>115</fpage>–<lpage>32</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3322/caac.21338" xlink:type="simple">10.3322/caac.21338</ext-link></comment> <object-id pub-id-type="pmid">26808342</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Luo</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Carter</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Miranda</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Lovell</surname> <given-names>JF</given-names></name>. <article-title>Chemophototherapy: An Emerging Treatment Option for Solid Tumors</article-title>. <source>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</source>. <year>2017</year>;<volume>4</volume>(<issue>1</issue>):<fpage>1600106</fpage>. Epub 2017/01/21.</mixed-citation></ref>
<ref id="pone.0176822.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gibney</surname> <given-names>GT</given-names></name>, <name name-style="western"><surname>Weiner</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Atkins</surname> <given-names>MB</given-names></name>. <article-title>Predictive biomarkers for checkpoint inhibitor-based immunotherapy</article-title>. <source>The Lancet Oncology</source>. <year>2016</year>;<volume>17</volume>(<issue>12</issue>):<fpage>e542</fpage>–<lpage>e51</lpage>. Epub 2016/12/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1470-2045(16)30406-5" xlink:type="simple">10.1016/S1470-2045(16)30406-5</ext-link></comment> <object-id pub-id-type="pmid">27924752</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Teng</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Kong</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Meng</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>J</given-names></name>. <article-title>Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges</article-title>. <source>Cancer letters</source>. <year>2015</year>;<volume>365</volume>(<issue>1</issue>):<fpage>23</fpage>–<lpage>9</lpage>. Epub 2015/05/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.canlet.2015.05.012" xlink:type="simple">10.1016/j.canlet.2015.05.012</ext-link></comment> <object-id pub-id-type="pmid">25980820</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boussiotis</surname> <given-names>VA</given-names></name>. <article-title>Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>375</volume>(<issue>18</issue>):<fpage>1767</fpage>–<lpage>78</lpage>. Epub 2016/11/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMra1514296" xlink:type="simple">10.1056/NEJMra1514296</ext-link></comment> <object-id pub-id-type="pmid">27806234</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sznol</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>L</given-names></name>. <article-title>Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer</article-title>. <source>Clinical cancer research: an official journal of the American Association for Cancer Research</source>. <year>2013</year>;<volume>19</volume>(<issue>5</issue>):<fpage>1021</fpage>–<lpage>34</lpage>. Epub 2013/03/06. PubMed Central PMCID: PMCPMC3702373.</mixed-citation></ref>
<ref id="pone.0176822.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Costa</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Carneiro</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Agulnik</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Rademaker</surname> <given-names>AW</given-names></name>, <name name-style="western"><surname>Pai</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Villaflor</surname> <given-names>VM</given-names></name>, <etal>et al</etal>. <article-title>Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials</article-title>. <source>Oncotarget</source>. <year>2016</year>. Epub 2016/11/17.</mixed-citation></ref>
<ref id="pone.0176822.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Xie</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Arai</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Shi</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Shi</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis</article-title>. <source>Oncotarget</source>. <year>2016</year>;<volume>7</volume>(<issue>45</issue>):<fpage>73068</fpage>–<lpage>79</lpage>. Epub 2016/09/30. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.12230" xlink:type="simple">10.18632/oncotarget.12230</ext-link></comment> <object-id pub-id-type="pmid">27683031</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gandini</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Massi</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Mandala</surname> <given-names>M</given-names></name>. <article-title>PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis</article-title>. <source>Critical reviews in oncology/hematology</source>. <year>2016</year>;<volume>100</volume>:<fpage>88</fpage>–<lpage>98</lpage>. Epub 2016/02/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.critrevonc.2016.02.001" xlink:type="simple">10.1016/j.critrevonc.2016.02.001</ext-link></comment> <object-id pub-id-type="pmid">26895815</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aguiar</surname> <given-names>PN</given-names> <suffix>Jr.</suffix></name>, <name name-style="western"><surname>Santoro</surname> <given-names>IL</given-names></name>, <name name-style="western"><surname>Tadokoro</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>de Lima</surname> <given-names>Lopes G</given-names></name>, <name name-style="western"><surname>Filardi</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Oliveira</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis</article-title>. <source>Immunotherapy</source>. <year>2016</year>;<volume>8</volume>(<issue>4</issue>):<fpage>479</fpage>–<lpage>88</lpage>. Epub 2016/03/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2217/imt-2015-0002" xlink:type="simple">10.2217/imt-2015-0002</ext-link></comment> <object-id pub-id-type="pmid">26973128</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>YX</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>XS</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>YF</given-names></name>, <name name-style="western"><surname>Hu</surname> <given-names>XC</given-names></name>, <name name-style="western"><surname>Yan</surname> <given-names>JQ</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>YL</given-names></name>, <etal>et al</etal>. <article-title>Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis</article-title>. <source>OncoTargets and therapy</source>. <year>2016</year>;<volume>9</volume>:<fpage>2649</fpage>–<lpage>54</lpage>. Epub 2016/05/27. PubMed Central PMCID: PMCPMC4863684. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2147/OTT.S102616" xlink:type="simple">10.2147/OTT.S102616</ext-link></comment> <object-id pub-id-type="pmid">27226727</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lian</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Zhu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Kong</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis</article-title>. <source>Targeted oncology</source>. <year>2016</year>;<volume>11</volume>(<issue>6</issue>):<fpage>753</fpage>–<lpage>61</lpage>. Epub 2016/07/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11523-016-0451-8" xlink:type="simple">10.1007/s11523-016-0451-8</ext-link></comment> <object-id pub-id-type="pmid">27422273</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wu</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Chai</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>J</given-names></name>. <article-title>PD-L1 and Survival in Solid Tumors: A Meta-Analysis</article-title>. <source>PloS one</source>. <year>2015</year>;<volume>10</volume>(<issue>6</issue>):<fpage>e0131403</fpage>. Epub 2015/06/27. PubMed Central PMCID: PMCPMC4483169. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0131403" xlink:type="simple">10.1371/journal.pone.0131403</ext-link></comment> <object-id pub-id-type="pmid">26114883</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Du</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Abedalthagafi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Aizer</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>McHenry</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Bray</surname> <given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma</article-title>. <source>Oncotarget</source>. <year>2015</year>;<volume>6</volume>(<issue>7</issue>):<fpage>4704</fpage>–<lpage>16</lpage>. Epub 2015/01/23. PubMed Central PMCID: PMCPMC4467109. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.3082" xlink:type="simple">10.18632/oncotarget.3082</ext-link></comment> <object-id pub-id-type="pmid">25609200</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Paiva</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Azpilikueta</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Puig</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ocio</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Sharma</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Oyajobi</surname> <given-names>BO</given-names></name>, <etal>et al</etal>. <article-title>PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma</article-title>. <source>Leukemia</source>. <year>2015</year>;<volume>29</volume>(<issue>10</issue>):<fpage>2110</fpage>–<lpage>3</lpage>. Epub 2015/03/18. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/leu.2015.79" xlink:type="simple">10.1038/leu.2015.79</ext-link></comment> <object-id pub-id-type="pmid">25778100</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Koirala</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Roth</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Gill</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Piperdi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chinai</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Geller</surname> <given-names>DS</given-names></name>, <etal>et al</etal>. <article-title>Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>30093</fpage>. Epub 2016/07/28. PubMed Central PMCID: PMCPMC4960483. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/srep30093" xlink:type="simple">10.1038/srep30093</ext-link></comment> <object-id pub-id-type="pmid">27456063</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Powles</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Eder</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Fine</surname> <given-names>GD</given-names></name>, <name name-style="western"><surname>Braiteh</surname> <given-names>FS</given-names></name>, <name name-style="western"><surname>Loriot</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Cruz</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer</article-title>. <source>Nature</source>. <year>2014</year>;<volume>515</volume>(<issue>7528</issue>):<fpage>558</fpage>–<lpage>62</lpage>. Epub 2014/11/28. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature13904" xlink:type="simple">10.1038/nature13904</ext-link></comment> <object-id pub-id-type="pmid">25428503</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Herbst</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>Soria</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Kowanetz</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Fine</surname> <given-names>GD</given-names></name>, <name name-style="western"><surname>Hamid</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Gordon</surname> <given-names>MS</given-names></name>, <etal>et al</etal>. <article-title>Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients</article-title>. <source>Nature</source>. <year>2014</year>;<volume>515</volume>(<issue>7528</issue>):<fpage>563</fpage>–<lpage>7</lpage>. Epub 2014/11/28. PubMed Central PMCID: PMCPMC4836193. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature14011" xlink:type="simple">10.1038/nature14011</ext-link></comment> <object-id pub-id-type="pmid">25428504</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bellmunt</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Mullane</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Werner</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Fay</surname> <given-names>AP</given-names></name>, <name name-style="western"><surname>Callea</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Leow</surname> <given-names>JJ</given-names></name>, <etal>et al</etal>. <article-title>Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma</article-title>. <source>Annals of Oncology</source>. <year>2015</year>;<volume>26</volume>(<issue>4</issue>):<fpage>812</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/annonc/mdv009" xlink:type="simple">10.1093/annonc/mdv009</ext-link></comment> <object-id pub-id-type="pmid">25600565</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boger</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Behrens</surname> <given-names>HM</given-names></name>, <name name-style="western"><surname>Mathiak</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kruger</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kalthoff</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Rocken</surname> <given-names>C</given-names></name>. <article-title>PD-L1 is an independent prognostic predictor in gastric cancer of Western patients</article-title>. <source>Oncotarget</source>. <year>2016</year>;<volume>7</volume>(<issue>17</issue>):<fpage>24269</fpage>–<lpage>83</lpage>. Epub 2016/03/25. PubMed Central PMCID: PMCPMC5029700. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.8169" xlink:type="simple">10.18632/oncotarget.8169</ext-link></comment> <object-id pub-id-type="pmid">27009855</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Choueiri</surname> <given-names>TK</given-names></name>, <name name-style="western"><surname>Fay</surname> <given-names>AP</given-names></name>, <name name-style="western"><surname>Gray</surname> <given-names>KP</given-names></name>, <name name-style="western"><surname>Callea</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ho</surname> <given-names>TH</given-names></name>, <name name-style="western"><surname>Albiges</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>PD-L1 expression in nonclear-cell renal cell carcinoma</article-title>. <source>Annals of Oncology</source>. <year>2014</year>;<volume>25</volume>(<issue>11</issue>):<fpage>2178</fpage>–<lpage>84</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/annonc/mdu445" xlink:type="simple">10.1093/annonc/mdu445</ext-link></comment> <object-id pub-id-type="pmid">25193987</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Darb-Esfahani</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kunze</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Kulbe</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Sehouli</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wienert</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lindner</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma</article-title>. <source>Oncotarget</source>. <year>2016</year>;<volume>7</volume>(<issue>2</issue>):<fpage>1486</fpage>–<lpage>99</lpage>. Epub 2015/12/02. PubMed Central PMCID: PMCPMC4811475. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.6429" xlink:type="simple">10.18632/oncotarget.6429</ext-link></comment> <object-id pub-id-type="pmid">26625204</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hatogai</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kitano</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Fujii</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kojima</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Daiko</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Nomura</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma</article-title>. <source>Oncotarget</source>. <year>2016</year>;<volume>7</volume>(<issue>30</issue>):<fpage>47252</fpage>–<lpage>64</lpage>. Epub 2016/06/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.10055" xlink:type="simple">10.18632/oncotarget.10055</ext-link></comment> <object-id pub-id-type="pmid">27322149</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hou</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Xiang</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer</article-title>. <source>Experimental and Molecular Pathology</source>. <year>2014</year>;<volume>96</volume>(<issue>3</issue>):<fpage>284</fpage>–<lpage>91</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.yexmp.2014.03.005" xlink:type="simple">10.1016/j.yexmp.2014.03.005</ext-link></comment> <object-id pub-id-type="pmid">24657498</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jo</surname> <given-names>J-C</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>H-J</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Chae</surname> <given-names>SW</given-names></name>, <etal>et al</etal>. <article-title>Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type</article-title>. <source>Annals of Hematology</source>. <year>2016</year>;<volume>96</volume>(<issue>1</issue>):<fpage>25</fpage>–<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00277-016-2818-4" xlink:type="simple">10.1007/s00277-016-2818-4</ext-link></comment> <object-id pub-id-type="pmid">27696202</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref027"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Newcastle–Ottawa quality assessment scale cohort studies 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf" xlink:type="simple">http://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf</ext-link>.</mixed-citation></ref>
<ref id="pone.0176822.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Deeks</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>. <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ (Clinical research ed)</source>. <year>2003</year>;<volume>327</volume>(<issue>7414</issue>):<fpage>557</fpage>–<lpage>60</lpage>. Epub 2003/09/06. PubMed Central PMCID: PMCPMC192859.</mixed-citation></ref>
<ref id="pone.0176822.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Davey Smith</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname> <given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ (Clinical research ed)</source>. <year>1997</year>;<volume>315</volume>(<issue>7109</issue>):<fpage>629</fpage>–<lpage>34</lpage>. Epub 1997/10/06. PubMed Central PMCID: PMCPMC2127453.</mixed-citation></ref>
<ref id="pone.0176822.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source>. <year>1994</year>;<volume>50</volume>(<issue>4</issue>):<fpage>1088</fpage>–<lpage>101</lpage>. Epub 1994/12/01. <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kawazoe</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kuwata</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kuboki</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Shitara</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Nagatsuma</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>Aizawa</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients</article-title>. <source>Gastric Cancer</source>. <year>2016</year>.</mixed-citation></ref>
<ref id="pone.0176822.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>HR</given-names></name>, <name name-style="western"><surname>Ha</surname> <given-names>S-J</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Heo</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Koh</surname> <given-names>YW</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>EC</given-names></name>, <etal>et al</etal>. <article-title>PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients</article-title>. <source>Scientific Reports</source>. <year>2016</year>;<volume>6</volume>:<fpage>36956</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/srep36956" xlink:type="simple">10.1038/srep36956</ext-link></comment> <object-id pub-id-type="pmid">27841362</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kiyasu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Miyoshi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Hirata</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Arakawa</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Ichikawa</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Niino</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma</article-title>. <source>Blood</source>. <year>2015</year>;<volume>126</volume>(<issue>19</issue>):<fpage>2193</fpage>–<lpage>201</lpage>. Epub 2015/08/05. PubMed Central PMCID: PMCPMC4635115. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2015-02-629600" xlink:type="simple">10.1182/blood-2015-02-629600</ext-link></comment> <object-id pub-id-type="pmid">26239088</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Wetherilt</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Krishnamurti</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ma</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Styblo</surname> <given-names>TM</given-names></name>, <etal>et al</etal>. <article-title>Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer</article-title>. <source>American Journal of Clinical Pathology</source>. <year>2016</year>;<volume>146</volume>(<issue>4</issue>):<fpage>496</fpage>–<lpage>502</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/ajcp/aqw134" xlink:type="simple">10.1093/ajcp/aqw134</ext-link></comment> <object-id pub-id-type="pmid">27686176</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Paulsen</surname> <given-names>E-E</given-names></name>, <name name-style="western"><surname>Kilvaer</surname> <given-names>TK</given-names></name>, <name name-style="western"><surname>Khanehkenari</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Al-Saad</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Hald</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Andersen</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Assessing PDL-1 and PD-1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach</article-title>. <source>Clinical Lung Cancer</source>. <year>2016</year>.</mixed-citation></ref>
<ref id="pone.0176822.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saito</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Abe</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Kunita</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Yamashita</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Seto</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Fukayama</surname> <given-names>M</given-names></name>. <article-title>Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implications</article-title>. <source>Modern Pathology</source>. <year>2016</year>.</mixed-citation></ref>
<ref id="pone.0176822.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sun</surname> <given-names>WY</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>YK</given-names></name>, <name name-style="western"><surname>Koo</surname> <given-names>JS</given-names></name>. <article-title>Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies</article-title>. <source>Journal of Translational Medicine</source>. <year>2016</year>;<volume>14</volume>(<issue>1</issue>).</mixed-citation></ref>
<ref id="pone.0176822.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thompson</surname> <given-names>ED</given-names></name>, <name name-style="western"><surname>Zahurak</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Murphy</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Cornish</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Cuka</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Abdelfatah</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma</article-title>. <source>Gut</source>. <year>2016</year>:gutjnl-2015-310839.</mixed-citation></ref>
<ref id="pone.0176822.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Ren</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Baldridge</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Monn</surname> <given-names>MF</given-names></name>, <name name-style="western"><surname>Fisher</surname> <given-names>KW</given-names></name>, <etal>et al</etal>. <article-title>Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer</article-title>. <source>Molecular Diagnosis &amp; Therapy</source>. <year>2016</year>;<volume>20</volume>(<issue>2</issue>):<fpage>175</fpage>–<lpage>81</lpage>.</mixed-citation></ref>
<ref id="pone.0176822.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname> <given-names>C-Y</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>M-W</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>Y-L</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>C-T</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>P-C</given-names></name>. <article-title>Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma</article-title>. <source>European Journal of Cancer</source>. <year>2016</year>;<volume>57</volume>:<fpage>91</fpage>–<lpage>103</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ejca.2015.12.033" xlink:type="simple">10.1016/j.ejca.2015.12.033</ext-link></comment> <object-id pub-id-type="pmid">26901614</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zou</surname> <given-names>MX</given-names></name>, <name name-style="western"><surname>Peng</surname> <given-names>AB</given-names></name>, <name name-style="western"><surname>Lv</surname> <given-names>GH</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>XB</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>She</surname> <given-names>XL</given-names></name>, <etal>et al</etal>. <article-title>Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis</article-title>. <source>American journal of translational research</source>. <year>2016</year>;<volume>8</volume>(<issue>7</issue>):<fpage>3274</fpage>–<lpage>87</lpage>. Epub 2016/08/11. PubMed Central PMCID: PMCPMC4969465. <object-id pub-id-type="pmid">27508049</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tie</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ma</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Zhu</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Mao</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Shen</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Wei</surname> <given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials</article-title>. <source>International journal of cancer</source>. <year>2017</year>;<volume>140</volume>(<issue>4</issue>):<fpage>948</fpage>–<lpage>58</lpage>. Epub 2016/11/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/ijc.30501" xlink:type="simple">10.1002/ijc.30501</ext-link></comment> <object-id pub-id-type="pmid">27813059</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zeng</surname> <given-names>DQ</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>YF</given-names></name>, <name name-style="western"><surname>Ou</surname> <given-names>QY</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>XY</given-names></name>, <name name-style="western"><surname>Zhong</surname> <given-names>RZ</given-names></name>, <name name-style="western"><surname>Xie</surname> <given-names>CM</given-names></name>, <etal>et al</etal>. <article-title>Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer</article-title>. <source>Oncotarget</source>. <year>2016</year>;<volume>7</volume>(<issue>12</issue>):<fpage>13765</fpage>–<lpage>81</lpage>. Epub 2016/02/13. PubMed Central PMCID: PMCPMC4924677. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.7282" xlink:type="simple">10.18632/oncotarget.7282</ext-link></comment> <object-id pub-id-type="pmid">26871598</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pardoll</surname> <given-names>DM</given-names></name>. <article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title>. <source>Nat Rev Cancer</source>. <year>2012</year>;<volume>12</volume>(<issue>4</issue>):<fpage>252</fpage>–<lpage>64</lpage>. Epub 2012/03/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrc3239" xlink:type="simple">10.1038/nrc3239</ext-link></comment> <object-id pub-id-type="pmid">22437870</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>HR</given-names></name>, <name name-style="western"><surname>Ha</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Heo</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Koh</surname> <given-names>YW</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>EC</given-names></name>, <etal>et al</etal>. <article-title>PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients</article-title>. <source>Scientific reports</source>. <year>2016</year>;<volume>6</volume>:<fpage>36956</fpage>. Epub 2016/11/15. PubMed Central PMCID: PMCPMC5107906. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/srep36956" xlink:type="simple">10.1038/srep36956</ext-link></comment> <object-id pub-id-type="pmid">27841362</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hwang</surname> <given-names>WT</given-names></name>, <name name-style="western"><surname>Adams</surname> <given-names>SF</given-names></name>, <name name-style="western"><surname>Tahirovic</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Hagemann</surname> <given-names>IS</given-names></name>, <name name-style="western"><surname>Coukos</surname> <given-names>G</given-names></name>. <article-title>Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis</article-title>. <source>Gynecologic oncology</source>. <year>2012</year>;<volume>124</volume>(<issue>2</issue>):<fpage>192</fpage>–<lpage>8</lpage>. Epub 2011/11/02. PubMed Central PMCID: PMCPMC3298445. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ygyno.2011.09.039" xlink:type="simple">10.1016/j.ygyno.2011.09.039</ext-link></comment> <object-id pub-id-type="pmid">22040834</object-id></mixed-citation></ref>
<ref id="pone.0176822.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Gagnon-Bartsch</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Tan</surname> <given-names>IB</given-names></name>, <name name-style="western"><surname>Earle</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ruff</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Pettinger</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas</article-title>. <source>Gut</source>. <year>2015</year>;<volume>64</volume>(<issue>11</issue>):<fpage>1721</fpage>–<lpage>31</lpage>. Epub 2014/11/12. PubMed Central PMCID: PMCPMC4680172. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/gutjnl-2014-308252" xlink:type="simple">10.1136/gutjnl-2014-308252</ext-link></comment> <object-id pub-id-type="pmid">25385008</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>